Notes to the Company financial statements For the year ended 31 December 2017 44.
Adoption of new and revised standards The impact on the Company of new and revised standards is the same as for the Group.
Details are given in Note 1 to the consolidated financial statements.
Significant accounting policies Basis of accounting For all periods, up to and including the year ended 31 December 2016, the Company prepared its financial statements in accordance with International Financial Reporting Standards adopted for use in the European Union.
These financial statements, for the year ended 31 December 2017, are the first the Company has prepared in accordance with FRS 101 Reduced Disclosure Framework.
The transition to FRS 101 did not result in any material impact.
As permitted by FRS 101, the Company has taken advantage of the following exemptions from the requirements of IFRS as below: The following paragraphs of IAS 1, presentation of financial statements: 10 d, statement of cash flows: 16 statement of compliance with all IFRS : 38A requirements for minimal of two primary statements, including cash flow statements : 111 cash flow statement information : and IAS 7.
No individual profit and loss account is prepared as provided by section 408 of the Companies Act 2006.
The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those set out in Note 2 of the consolidated financial statements with the addition of the policies noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provision for impairment.
Equity-settled employee share schemes are accounted for in accordance with IFRS 2 Share based payments.
The current charge expenses relating to the subsidiaries employees are recharged to subsidiary companies.
Intangible assets Product related Goodwill intangibles Software Total $m $m $m $m Cost Balance at 1 January 2016 43 145 10 198 Additions transfers to subsidiaries 140 3 137 Transfer to investment in subsidiaries 43 43 Disposals 5 5 Balance at 1 January 2017 13 13 Additions 8 8 Balance at 31 December 2017 21 21 Amortisation Balance at 1 January 2016 1 1 Charge for the year 2 2 Transfers to subsidiaries 3 3 Balance at 1 January 2017 Charge for the year 1 1 Balance at 31 December 2017 1 1 Carrying amount At 31 December 2017 20 20 At 31 December 2016 13 13 Details of useful lives and amortisation rates are included in Note 14.
Investments in subsidiaries The details of Investment in subsidiaries are mentioned in Note 41.
The following table provides the movement of the investments in subsidiaries: 2017 2016 $m $m Beginning balance 3,179 1,888 Additions to subsidiaries 144 1,908 Transfer from Goodwill 43 Reduction in investment 650 Reduction in paid up capital 10 Ending balance 3,323 3,179 This category relates to an intragroup restructuring following the acquisition of West-Ward Columbus Inc.
In 2016, the capital of Hikma Finance Luxembourg SARL was reduced by $10 million.
Due from subsidiaries Non-current assets 2017 2016 $m $m West-Ward Pharmaceuticals Corp. 8 8 Hikma Italia S. p. A 4 4 Hikma MENA Holdings Limited 7 West-Ward Pharmaceuticals International Limited 167 488 Hikma UK Limited 183 362 507 Current assets 2017 2016 $m $m Hikma Pharmaceuticals LLC 3 Hikma UK Limited 55 62 Hikma MENA Holdings Limited 5 7 West-Ward Pharmaceuticals Corp. 4 33 Hikma Pharma SAE 3 2 Hikma Farmaceutica, Portugal S. A.
1 Hikma Emerging Markets and Asia Pacific FZ-LLC 3 1 71 108 175 175 Hikma Pharmaceuticals PLC Notes to the Company financial statements continued 49.
Other current assets 2017 2016 $m $m Price adjustment receivable 61 34 Investment designated at fair value 22 20 Co-development and earnout receivable 3 Others 3 2 86 59 Price adjustment receivable: in respect to Note 18 this represents the current portion of the contingent receivables in relation to the West-Ward Columbus acquisition.
In addition, the Group was entitled to be reimbursed with $30 million from the seller of a previous acquisition if certain regulatory conditions existed as of 24 December 2017.
Investment designated at fair value: represents the agreement the Group entered into with an asset management firm in 2015 to manage a $20 million portfolio of underlying debt instruments.
The investment comprises a portfolio of assets that are managed by an asset manager and is measured at fair value: any changes in fair value go through other comprehensive income.
This asset is classified as level 1 as it uses quoted prices in active markets.
Cash and cash equivalents As at 31 December 2017 2016 $m $m Cash at banks and on hand 5 5 Time deposits 20 27 25 32 Cash and cash equivalents include highly liquid investments with maturities of three months or less which is convertible to known amounts of cash and are subject to insignificant risk of changes in value.
Other payables Management consider that the carrying amount of other payables approximates to their fair value.
Due to subsidiaries Non-current liabilities 2017 2016 $m $m Hikma Maple Limited 44 44 Hikma Investment LLC 1 1 Hikma Pharmaceuticals LLC 10 Eurohealth International SARL 10 Hikma MENA Holdings Limited 60 115 55 176 Financial statements 52.
Due to subsidiaries continued Current liabilities 2017 2016 $m $m Hikma Investment LLC 22 5 Thymoorgan GmbH 1 West-Ward Pharmaceuticals International Limited 15 24 Hikma Pharma Limited 2 2 39 32 53.
Long-term financial debts The balance comprises mainly of a $500 million carrying value of $496 million, and fair value of $502 million 4.25% Eurobond due April 2020 with the rating of BB Ba1 and a withdrawal of $112 million on the syndicated revolving credit facility Note 28.
Financial policies for risk management and their objectives Currency risk Currency risks as defined by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency.
A sensitivity analysis based on a 10% movement in foreign exchange rates has no material impact on the Company results and Company statement of changes in equity.
Further details on how the Company manages the currency risk are given in Note 30.
Interest rate risk As at As at 31 December 31 December 2017 2016 Fixed rate Floating rate Total Fixed rate Floating rate Total $m $m $m $m $m $m Financial liabilities Interest-bearing loans and borrowings 496 112 608 495 145 640 Financial assets Cash and cash equivalents 20 20 27 27 An interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31 December 2017, with all other variables held constant.
Based on the composition of the Company debt and cash portfolio as at 31 December 2017, a 1% increase in interest rates would result in an additional interest expense of $1 million being incurred per year 2016: $1 million of interest income incurred.
177 177 Hikma Pharmaceuticals PLC Notes to the Company financial statements continued 54.
Financial policies for risk management and their objectives continued Liquidity risk Less than Two to one year five years Total 2017 $m $m $m Cash and cash equivalents 25 25 Other receivables 3 3 Interest bearing loans and borrowings 22 643 665 Other payables 4 4 2 643 641 Less than Two to one year five years Total 2016 $m $m $m Cash and cash equivalents 32 32 Other receivables 2 2 Interest bearing loans and borrowings 24 702 726 Other payables 4 4 6 702 696 The Company believes that, given the Groups operating cash flow during 2017, it has the ability to satisfy its liability commitments.
Staff costs Hikma Pharmaceuticals PLC currently has an average of 30 employees 2016: 21 employees excluding Executive Directors : total compensation paid to them amounted to $8 million 2016: $6 million of which salaries and bonuses compromise an amount of $6 million 2016: $5 million the remaining balance of $2 million 2016: $1 million represents national insurance contributions.
The cost of share-based payments and other benefits is represented below.
Share based payment Executive incentive plans EIPs The details of the EIP scheme are provided in Note 38.
As at 31 December 2017, the total number of awards granted to employees of the Company under the EIP during the life of the plans was 554,700 shares 2016: 364,274 and the total amount of the compensation expenses charged to profit and loss is $5.4 million 2016: $3 million.
Management incentive plans MIPs The details of the MIP scheme are provided in Note 38.
As at 31 December 2017, the total number of awards granted to employees of the Company under the MIP during the life of the plans was 31,316 shares 2016: 25,716 and the total amount of the compensation expenses charged to profit and loss is $0.2 million 2016: $0.2 million.
Long-term incentive plans LTIPs The details of the long-term incentive plan LTIPs are provided in Note 38.
As at 31 December 2017, the total number of awards granted to employees of the Company under the LTIPs during the life of the plans was 1,649,615 shares 2016: 1,649,615.
A true up of $0.3 million has been credited to profit and loss 2016: $2 million charged to profit and loss.
Share premium Share premium $m Balance at 1 January and 31 December 2017 282 59.
Profit for the year The net income in the Company for the year is $12 million 2016: $77 million.
Included in the net income for the year is an amount of $16 million 2016: $125 million representing dividends received, $29 million contingent consideration gain Note 5 included in the other operating income 2016: $nil, and $5 million 2016: $5 million representing the current year charge of share based payments.
The remaining $16 million 2016: $17 million of the Groups share based payment charge is recharged to subsidiary companies.
The remaining income statement components represent general and administrative expenses.
Audit fees for the Company are borne by the Group Note 6.
Related Parties Amounts repayable to and from subsidiaries are disclosed in Notes 48 and 52.
Other transactions with related parties include management charges for services provided to the subsidiary companies, equity settled employee share scheme costs relating to the subsidiary companies and transactions with key management personnel.
Compensation paid to key management personnel is disclosed in Note 40.
Details of Directors remuneration are disclosed in the Remuneration Committee Report on pages 86 to 108.
More details on the general information of the ultimate parent of the Group are disclosed in Note 2.
Contingent liabilities A contingent liability existed at the balance sheet date in respect to a standby letter of credit totalling $9 million 2016: $9 million for a potential stamp duty obligation that may arise for repayment of a loan by intercompany guarantors.
It is not probable that the repayment will be made by the intercompany guarantors, accordingly, no provision for any liability has been made in these financial statements.
179 179 Hikma Pharmaceuticals PLC Shareholder information Shareholder information 2018 financial calendar Share listings London Stock Exchange 5 April 2017 final dividend ex-dividend date The Companys Ordinary Shares are admitted to the Official List of the 6 April 2017 final dividend record date London Stock Exchange.
They are listed under EPIC HIK, SEDOL B0LCW08 GB and ISIN GB00B0LCW083.
18 May Annual General Meeting 24 May 2017 final dividend paid to shareholders Further information on this market, its trading systems and current trading in Hikma Pharmaceuticals PLC shares can be found on the 15 August 2017 interim results and interim dividend London Stock Exchange website www.
announced 23 August 2018 interim dividend ex-dividend date Global Depository Receipts The Company also has listed Global Depository Receipts GDRs 24 August 2018 interim dividend record date on the Nasdaq Dubai.
They are listed under EPIC HIK and ISIN 21 September 2018 interim dividend paid to shareholders US4312882081.
Further information on the Nasdaq Dubai, its trading systems and current trading in Hikma Pharmaceuticals PLC GDRs Provisional dates can be found on the website www.
Shareholding enquiries American Depository Receipts ADRs Enquiries or information concerning existing shareholdings should Hikma Pharmaceuticals PLC has an ADR programme for which be directed to the Companys registrars, Link Registrars either: BNY Mellon acts as Depository.
One ADR equates to 2 Hikma Ordinary Shares.
ADRs are traded as a Level 1 OTC programme under the in writing to Shareholder Services, Link Registrars, 34 Beckenham symbol HKMPY.
Enquiries should be made to: Road, Beckenham, Kent BR3 4TU by telephone from within the UK on 0871 664 0300 BNY Mellon Shareowner Services by telephone from outside the UK on 44 371 664 0300 or PO Box 358516 by email enquiries@linkgroup.
co. uk Pittsburgh, PA 15252-8516 Tel: 1 201 680 6825 Dividend payments Currency Tel: 1 888 BNY ADRS toll-free within the US The Company declares dividends in US Dollars.
Unless you have E-mail: shrrelations@bnymellon.
com elected otherwise, you will receive your dividend in US Dollars.
Shareholders can opt to receive the dividend in Pounds Sterling or Shareholder fraud Jordanian Dinars.
The Registrar retains records of the dividend currency The Financial Conduct Authority has issued a number of warnings to for each shareholder and only changes them at the shareholders shareholders regarding boiler room scams.
Over the last year many request.
If you wish to change the currency in which you receive your companies have become aware that shareholders have received dividend please contact the Registrars.
unsolicited phone calls or correspondence concerning investment matters.
These are typically from overseas based brokers who target Dividend payments Bank Transfer UK shareholders, offering to sell them what often turn out to be worthless Shareholders who currently receive their dividend by cheque can or high risk shares in US or UK investments.
These operations are request a dividend mandate form from the Registrar and have their commonly known as boiler rooms.
These brokers can be very persistent dividend paid direct into their bank account on the same day as the and extremely persuasive.
Shareholders are advised to be very cautious dividend is paid.
The tax voucher is sent direct to the shareholders of unsolicited advice, offers to buy shares at a discount or offers of free registered address.
If you receive any unsolicited investment advice: Obtain the correct name of the person and organisations: Dividend payments International Payment System If you are an overseas shareholder the Registrar is now able to pay Check they are authorised by the FCA by looking the firm up on dividends in several foreign currencies for an administrative charge www.
uk register: of 5.00, which is deducted from the payment.
Contact the Registrar Report the matter to the FCA either by calling 0800 111 6768 or visit for further information.
uk consumers: If the caller persists, hang up.
Website Press releases, the share price and other information on the Group Details of the share dealing facilities sponsored by the Company are available on the Companys website www.
are included in Company mailings and are on the Company website.
The Companys website is www.
com and the registered office is 1 New Burlington Place, London W1S 2HR.
180 Principal Group Companies Hikma Pharmaceuticals PLC Advisers Registered in England and Wales number 5557934 Auditors Registered office:  LLP 1 New Burlington Place 1 Embankment Place London W1S 2HR London WC2N 6RH UK UK Telephone: 44 0 20 7399 2760 Facsimile: 44 0 20 7399 2761 Brokers E-mail: investors@hikma.
com Citigroup Global Markets Limited Canada Square West-Ward Pharmaceutical Corp. London E14 5LB 401 Industrial Way West UK Eatontown Bank of America Merrill Lynch New Jersey 07724 2 King Edward Street US London EC1A 1HQ Telephone: 1 732 542 1191 UK Facsimile: 1 732 542 6150 Media Relations Hikma Pharmaceuticals LLC FTI Consulting P. O.
Box 182400 200 Aldersgate 11118 Amman Aldersgate Street Jordan London EC1A 4HD UK Telephone: 962 6 5802900 Facsimile: 962 6 5827102 Registrars Hikma Farmacutica Portugal S. A.
Link Registrars Estrada Rio Da Mo no.
8 34 Beckenham Road 8A, 8B Fervena Beckenham 2705 906 Terrugem SNT BR34 4TU Portugal Telephone: 351 21 9608410 Facsimile: 351 21 9615102 Printed in the UK by Pureprint using vegetable inks and their environmental printing technology.
Both manufacturing mill and the printer are registered to the Environmental Management System ISO14001 and are Forest Stewardship Council FSC chain-of-custody certified.
Designed and produced by Hikma Pharmaceuticals PLC Annual Report 2017 Hikma Pharmaceuticals PLC 1 New Burlington Place London W1S 2HR T 020 7399 2760 www.
